The Entelos Metabolism PhysioLab platform is an innovative and predictive computer model that simulates diabetic patients and can accurately predict the effects of drugs, changes in diet and exercise, and other interventions. The platform has already been used successfully with other pharmaceutical partners to select targets and compounds, find the best doses for patients, and support clinical trial design.
“We are pleased to be conducting in silico research for Lilly, who is a long time customer of Entelos’ predictive toxicology systems and other information products,” commented James Karis, President and CEO of Entelos. “We believe that our Metabolism platform enables more rapid assessment, evaluation, and testing of complex therapies to help accelerate R&D and we look forward to supporting Lilly’s programs.”
For further information please contact: Entelos, Inc. Jill Fujisaki, VP Investor Relations Tel: +1 650 572 5400 KBC Peel Hunt, Ltd (Nominated Advisor and Broker) Capel Irwin/David Anderson Tel +44 (0) 20 4718 8900 Buchanan Communications Lisa Baderoon / Mary-Jane Johnson Tel +44 (0) 20 7466 5000
